Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“